Carboxyl-terminal truncated HBx regulates a distinct microRNA transcription program in Hepatocellular carcinoma development

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Yip, Wing Kit ^a   Cheng, Alfred Sze Lok ^a   Zhu, Ranxu ^a   Lung, Raymond Wai Ming ^a   Tsang, Daisy Pui Fong ^a   Lau, Suki Shuk Kei ^a   Chen, Yangchao ^a   Sung, Jonathan Gabriel ^a   Lai, Paul Bo San ^a   Ng, Enders Kai On ^a,b   Yu, Jun ^a   Wong, Nathalie ^a   To, Ka Fai ^a   Wong, Vincent Wai Sun ^a   Sung, Joseph Jao Yiu ^a   Chan, Henry Lik Yuen ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VIRUS X PROTEIN; LUCIFERASE; MICRORNA; MICRORNA 146A; MICRORNA 190; MICRORNA 26A; MICRORNA 29C; RNA; UNCLASSIFIED DRUG; PRIMER DNA; TRANSACTIVATOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER TISSUE; CARBOXY TERMINAL SEQUENCE; CELL GROWTH; CELL STRAIN HEK293; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LENTIVIRINAE; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MALE; MICROARRAY ANALYSIS; NONHUMAN; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; TRANSCRIPTION REGULATION; AMINO ACID SEQUENCE; CELL TRANSFORMATION; CHEMISTRY; GENETIC TRANSCRIPTION; GENETICS; LIVER TUMOR; MOLECULAR CLONING; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; SEQUENCE HOMOLOGY;

HEPATITIS B VIRUS; LENTIVIRUS;

AMINO ACID SEQUENCE; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN IMMUNOPRECIPITATION; CLONING, MOLECULAR; COHORT STUDIES; DNA PRIMERS; HUMANS; LIVER NEOPLASMS; MICRORNAS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY, AMINO ACID; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC;

EID: 79961136142     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022888     Document Type: Article

References (68)

1. Feitelson MA, Duan LX, (1997) Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am J Pathol 150: 1141-1157.
2. Chan HL, Sung JJ, (2006) Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 26: 153-161.
3. Cheng AS, Chan HL, Leung WK, To KF, Go MY, et al. (2004) Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. Mod Pathol 17: 1169-1179.
4. Doria M, Klein N, Lucito R, Schneider RJ, (1995) The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. EMBO J 14: 4747-4757.
5. Diao J, Khine AA, Sarangi F, Hsu E, Iorio C, et al. (2001) X protein of hepatitis B virus inhibits Fas-mediated apoptosis and is associated with up-regulation of the SAPK/JNK pathway. J Biol Chem 276: 8328-8340.
6. Cheng AS, Yu J, Lai PB, Chan HL, Sung JJ, (2008) COX-2 mediates hepatitis B virus X protein abrogation of p53-induced apoptosis. Biochem Biophys Res Commun 374: 175-180.
7. Qadri I, Maguire HF, Siddiqui A, (1995) Hepatitis B virus transactivator protein X interacts with the TATA-binding protein. Proc Natl Acad Sci USA 92: 1003-1007.
8. Cougot D, Wu Y, Cairo S, Caramel J, Renard CA, et al. (2007) The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription. J Biol Chem 282: 4277-4287.
9. Park IY, Sohn BH, Yu E, Suh DJ, Chung YH, et al. (2007) Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology 132: 1476-1494.
10. Sirma H, Giannini C, Poussin K, Paterlini P, Kremsdorf D, et al. (1999) Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene 18: 4848-4859.
11. Tu H, Bonura C, Giannini C, Mouly H, Soussan P, et al. (2001) Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res 61: 7803-7810.
12. Iavarone M, Trabut JB, Delpuech O, Carnot F, Colombo M, et al. (2003) Characterisation of hepatitis B virus X protein mutants in tumour and non-tumour liver cells using laser capture microdissection. J Hepatol 39: 253-261.
13. Ma NF, Lau SH, Hu L, Xie D, Wu J, et al. (2008) COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis. Clin Cancer Res 14: 5061-5068.
14. Xu R, Zhang X, Zhang W, Fang Y, Zheng S, et al. (2007) Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma. Hepatology 46: 1810-1820.
15. Cheng AS, Wong N, Tse AM, Chan KY, Chan KK, et al. (2007) RNA interference targeting HBx suppresses tumor growth and enhances cisplatin chemosensitivity in human hepatocellular carcinoma. Cancer Lett 253: 43-52.
16. Wang X, Wang HK, McCoy JP, Banerjee NS, Rader JS, et al. (2009) Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA 15: 637-647.
17. Pichler K, Schneider G, Grassmann R, (2008) MicroRNA miR-146a and further oncogenesis-related cellular microRNAs are dysregulated in HTLV-1-transformed T lymphocytes. Retrovirology 5: 100.
18. Cameron JE, Yin Q, Fewell C, Lacey M, McBride J, et al. (2008) Epstein-Barr virus latent membrane protein 1 induces cellular MicroRNA miR-146a, a modulator of lymphocyte signaling pathways. J Virol 82: 1946-1958.
19. Wang Y, Lu Y, Toh ST, Sung WK, Tan P, et al. (2010) Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. J Hepatol 53: 57-66.
20. Brown JJ, Parashar B, Moshage H, Tanaka KE, Engelhardt D, et al. (2000) A long-term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in Rag-2-deficient mice. Hepatology 31: 173-181.
21. Cheng B, Zheng Y, Guo X, Wang Y, Liu C, (2010) Hepatitis B viral X protein alters the biological features and expressions of DNA repair enzymes in LO2 cells. Liver Int 30: 319-326.
22. Sung JJ, Tsui SK, Tse CH, Ng EY, Leung KS, et al. (2008) Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus. J Virol 82: 3604-3611.
23. Araki K, Akagi K, Miyazaki J, Matsubara K, Yamamura K, (1990) Correlation of tissue-specific methylation with gene inactivity in hepatitis B virus transgenic mice. Jpn J Cancer Res 81: 1265-1271.
24. Chen Y, Lin MC, Yao H, Wang H, Zhang AQ, et al. (2007) Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 46: 200-208.
25. Cheng AS, Jin VX, Fan M, Smith LT, Liyanarachchi S, et al. (2006) Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. Mol Cell 21: 393-404.
26. Lung RW, Tong JH, Sung YM, Leung PS, Ng DC, et al. (2009) Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia 11: 1174-1184.
27. Kim CM, Koike K, Saito I, Miyamura T, Jay G, (1991) HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351: 317-320.
28. Chan HL, Hui AY, Wong ML, Tse AM, Hung LC, et al. (2004) Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 53: 1494-1498.
29. Chan HL, Tse CH, Mo F, Koh J, Wong VW, et al. (2008) High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 26: 177-182.
30. Lu J, He ML, Wang L, Chen Y, Liu X, et al. (2011) MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 71: 225-233.
31. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, et al. (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005-1017.
32. Ji Y, He Y, Liu L, Zhong X, (2010) MiRNA-26b regulates the expression of cyclooxygenase-2 in desferrioxamine-treated CNE cells. FEBS Lett 584: 961-967.
33. Ma YL, Zhang P, Wang F, Moyer MP, Yang JJ, et al. (2010) Human embryonic stem cells and metastatic colorectal cancer cells shared the common endogenous human microRNA-26b. J Cell Mol Med In press.
34. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, et al. (2010) Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 51: 836-845.
35. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, et al. (2007) MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 104: 15805-15810.
36. Marton S, Garcia MR, Robello C, Persson H, Trajtenberg F, et al. (2008) Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia 22: 330-338.
37. Kumar M, Lu Z, Takwi AA, Chen W, Callander NS, et al. (2011) Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 30: 843-853.
38. Lin SL, Chiang A, Chang D, Ying SY, (2008) Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14: 417-424.
39. Braconi C, Valeri N, Gasparini P, Huang N, Taccioli C, et al. (2010) Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin Cancer Res 16: 957-966.
40. Xu C, Liu S, Fu H, Li S, Tie Y, et al. (2010) MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur J Cancer 46: 2828-2836.
41. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, et al. (2009) Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 35: 856-867.
42. Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, et al. (2011) MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem 286: 420-428.
43. Maes OC, Sarojini H, Wang E, (2009) Stepwise up-regulation of microRNA expression levels from replicating to reversible and irreversible growth arrest states in WI-38 human fibroblasts. J Cell Physiol 221: 109-119.
44. Bock CT, Toan NL, Koeberlein B, Song le H, Chin R, et al. (2008) Subcellular mislocalization of mutant hepatitis B X proteins contributes to modulation of STAT/SOCS signaling in hepatocellular carcinoma. Intervirology 51: 432-443.
45. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, et al. (2008) Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 14: 419-427.
46. Li W, Xie L, He X, Li J, Tu K, et al. (2008) Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 123: 1616-1622.
47. Wong QW, Ching AK, Chan AW, Choy KW, To KF, et al. (2010) MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res 16: 867-875.
48. Su H, Yang JR, Xu T, Huang J, Xu L, et al. (2009) MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 69: 1135-1142.
49. Wong QW, Lung RW, Law PT, Lai PB, Chan KY, et al. (2008) MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 135: 257-269.
50. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, et al. (2009) Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 49: 1098-1112.
51. Chen J, Feilotter HE, Pare GC, Zhang X, Pemberton JG, et al. (2010) MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol 176: 2520-2529.
52. Li XF, Yan PJ, Shao ZM, (2009) Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene 28: 3937-3948.
53. Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, et al. (2010) miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer 127: 1363-1372.
54. Su F, Schneider RJ, (1997) Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Proc Natl Acad Sci USA 94: 8744-8749.
55. Lee AT, Ren J, Wong ET, Ban KH, Lee LA, et al. (2005) The hepatitis B virus X protein sensitizes HepG2 cells to UV light-induced DNA damage. J Biol Chem 280: 33525-33535.
56. Su JM, Lai XM, Lan KH, Li CP, Chao Y, et al. (2007) X protein of hepatitis B virus functions as a transcriptional corepressor on the human telomerase promoter. Hepatology 46: 402-413.
57. Han J, Ding L, Yuan B, Yang X, Wang X, et al. (2006) Hepatitis B virus X protein and the estrogen receptor variant lacking exon 5 inhibit estrogen receptor signaling in hepatoma cells. Nucleic Acids Res 34: 3095-3106.
58. Sung WK, Lu Y, Lee CW, Zhang D, Ronaghi M, et al. (2009) Deregulated direct targets of the hepatitis B virus (HBV) protein, HBx, identified through chromatin immunoprecipitation and expression microarray profiling. J Biol Chem 284: 21941-21954.
59. Xu H, He JH, Xiao ZD, Zhang QQ, Chen YQ, et al. (2010) Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology 52: 1431-1442.
60. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, et al. (2008) MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 112: 4202-4212.
61. Tsang DP, Cheng AS, (2011) Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J Gastroenterol Hepatol 26: 19-27.
62. Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, et al. (2011) EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cancer Res 71: 4028-4039.
63. Fabbri M, (2008) MicroRNAs and cancer epigenetics. Curr Opin Investig Drugs 9: 583-590.
64. Ji J, Shi J, Budhu A, Yu Z, Forgues M, et al. (2009) MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361: 1437-1447.
65. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, et al. (2008) NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 14: 369-381.
66. Park SY, Lee JH, Ha M, Nam JW, Kim VN, (2009) miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 16: 23-29.
67. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, et al. (2009) Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 69: 1279-1283.
68. Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, et al. (2008) MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A 105: 5874-5878.